Truist lowered the firm’s price target on DaVita (DVA) to $164 from $170 and keeps a Hold rating on the shares. The firm has adjusted its estimates to reflect the company’s Q1 results and notes that while it remains positive on its core dialysis business and the potential opportunity tied to integrated care longer term, it also views its near-term fundamentals as mixed, with improved capital efficiency to be somewhat offset by slower organic volume trends, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVA:
- DaVita price target lowered to $157 from $165 at TD Cowen
- DaVita’s Resilience Amidst Challenges: Hold Rating Maintained Despite Q1 Setbacks and Adjusted Price Target
- Coca-Cola Stock (KO) Remains a Berkshire Hathaway Favorite
- DaVita’s Earnings Call: Balancing Achievements and Challenges
- Berkshire Hathaway exits positions in Citigroup, Nubank